Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $34.40

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $34.40.

Several equities research analysts have weighed in on ENGN shares. Guggenheim started coverage on enGene in a research report on Monday, April 15th. They issued a “buy” rating and a $34.00 target price on the stock. Wells Fargo & Company assumed coverage on enGene in a report on Monday, April 22nd. They set an “overweight” rating and a $30.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. SVB Leerink began coverage on enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Morgan Stanley began coverage on enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 target price for the company.

Insider Buying and Selling

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the sale, the insider now directly owns 3,036,153 shares in the company, valued at $45,542,295. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Trading of enGene

A number of institutional investors have recently added to or reduced their stakes in ENGN. Vivo Capital LLC bought a new position in shares of enGene in the fourth quarter valued at approximately $6,264,000. BVF Inc. IL bought a new position in shares of enGene in the fourth quarter valued at approximately $20,777,000. Omega Fund Management LLC bought a new position in shares of enGene in the fourth quarter valued at approximately $10,441,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of enGene in the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Trading Up 5.3 %

Shares of NASDAQ ENGN opened at $15.50 on Monday. enGene has a 1-year low of $6.69 and a 1-year high of $43.00. The stock has a fifty day moving average of $16.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.